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Abstract: Chronic congestive heart failure (HF) occurs in infants and children as a result 
of systemic ventricle incompetence. Neurohormonal activation is thought to be the main 
consequence of cardiac pump failure and cause of further worsening. Several large multicenter 
randomized trials have demonstrated that beta-adrenergic blocking agents can improve 
ventricular ejection fraction, symptoms, and survival in adults with chronic congestive HF. 
Current literature about pediatric HF is very scarce. The only large, multicenter, randomized, 
placebo-controlled pediatric trial failed to demonstrate any beneﬁ  cial effect of beta-blockers in 
infants and children with chronic HF. Other small-size reports showed signiﬁ  cant improvement 
in ejection fraction and/or clinical outcomes. The HF pediatric population is characterized by 
wide heterogeneicity regarding causes, underlying cardiac disease, drug pharmacokinetics, 
and interactions, which may account for divergences. Further large-scale studies are needed to 
elucidate the optimal use (indications and dosages) of beta-blockers in the management of HF 
in children, with particular attention to the underlying cardiac disease.
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Introduction
Chronic congestive heart failure (HF) is an ongoing problem in pediatric patients 
with cardiac disease, characterized by a high risk for morbidity and mortality. The 
physiopathological mechanisms of HF have been widely explored in adults (Lowes 
et al 1999; Francis 2001; Buchhorn et al 2003). Numerous trials have demonstrated 
the beneﬁ  cial impact of newer agents on prognosis and survival in the adult HF 
population (Lechat et al 1998). Only scarce literature is available regarding both 
mechanisms and treatment of HF in the pediatric population. Most of the practice in 
the management of HF in children is drawn from adult experience. In particular, the 
advantage of beta-adrenergic receptor antagonists in the pediatric HF population is 
still a matter of discussion.
The aims of this review are to give an overview of the mechanisms and causes 
of HF in children, and to assess current knowledge about efﬁ  cacy and tolerability of 
beta-receptor antagonist agents in the treatment of pediatric HF. This review will focus 
on chronic HF due to systemic ventricle systolic dysfunction.
Congestive HF
Deﬁ  nition
Congestive HF is deﬁ  ned as inadequate oxygen delivery by the heart or the circulatory 
system to meet the demands of the body. It occurs when the compensatory mecha-
nisms of the body are overcome (Francis 2001). There is a tremendous heterogeneicity 
regarding the age, the mechanisms, the causes, and the manifestations of HF in children 
(O’Laughlin 1999; Kay et al 2001).Therapeutics and Clinical Risk Management 2007:3(5) 848
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Oxygen delivery is the product of oxygen content in the blood 
and cardiac output. Oxygen content is the arterial oxygen satu-
ration and cardiac output is the product of heart rate and stroke 
volume; the latter is a result of preload, afterload, and contractility 
conditions of the heart. Any alteration of one (or more) these 
three components may lead to the occurrence of HF.
Incidence
The incidence of HF in children depends on the underlying 
cardiac disease and the age of the patient. The annual inci-
dence of HF due to cardiomopathy in the ﬁ  rst year of life 
is as high as 4 cases per 100,000 live births (O’Laughlin 
1999; Kay et al 2001). It seems to be 16 times as high in 
patients less than 1 year old than in those more than 1 year. 
The prevalence of HF among patients with structural heart 
defects is unknown. Failure of the systemic ventricle may 
occur in patients with systemic right ventricle who had 
undergone Mustard or Senning operation (atrial bafﬂ  e switch 
correction of transposition of the great vessels), or in those 
with long-term Fontan-type palliation and functionally single 
ventricle (total cavo-pulmonary derivation).
Causes of HF in children
The causes of HF in children are very heterogeneous (Kay 
et al 2001). Congestive HF due to left to right shunts and/or 
left heart outﬂ  ow tract obstruction is mostly accessible to pal-
liative or reparative surgery (Auslender and Artman 2000).
Cardiomyopathy is the main cause of left ventricle fail-
ure. In these cases, myocardial dysfunction may be related 
to myocarditis or anthracycline toxicity or even metabolic 
diseases, or may be idiopathic and sometimes from genetic 
inheritance.
Of highest concern are the cases with chronic HF due to 
dysfunction of the systemic functional ventricle in the con-
text of congenital heart disease, either left ventricle or right 
ventricle or single ventricle. Failure of the systemic ventricle 
due to congenital structural abnormalities of the heart is an 
unique feature of the pediatric HF population. Not only left 
ventricle, but also systemic right or single ventricle dysfunc-
tion may be involved in the mechanisms of HF in children. 
Failure of reparative surgery, of Fontan-type single ventricle 
physiology, or of an overworked systemic right ventricle are 
crucial issues to address (Kay et al 2001).
Pathophysiological mechanisms of HF 
in children
Several mechanisms are activated to compensate for impaired 
cardiac output. HF results from inadequate tissue oxygen 
delivery and develops when the compensatory mechanisms 
are overhelmed or as a consequence of these mechanisms 
(O’Laughlin MP 1999; Francis 2001; Kay et al 2001).
The adaptative mechanisms aim to maintain perfusion of 
vital organs through: 1) maintenance of systemic pressure by 
vasoconstriction, 2) restoration of cardiac output by increasing 
heart rate, contractility, and extracellular volume (Figure 1).
The neurohormonal activation is thought to be the main 
adaptative mechanism in HF, but it aggravates the HF 
through detrimental consequences of activation (Hoch and 
Netz 2005).
In this setting, the activation of the renin-angiotensin 
system stimulates aldosterone and angiotensin II production. 
Subsequent salt and water retention results in increased pre-
load and angiotensin-induced peripheral vasoconstriction in 
increased afterload, in order to compensate for low cardiac 
output. Volume expansion is effective because increased 
venous return results in elevation of end-diastolic volume. 
The Franck Starling mechanism subsequently leads to dilata-
tion of the ventricular cavity which aims to enhance cardiac 
stroke volume. Additional activation of the sympathic ner-
vous system exacerbates the production of catecholamines 
and the stimulation of cardiac beta-receptors. Increases in 
myocardial contractility, heart rate, and wall stress are the 
main consequences of activation of the sympathetic nervous 
system. Sustained cardiac adrenergic activation results 
in desensitization of beta-adrenergic signal transduction 
mechanisms, downregulation of beta-receptor, and direct 
damage to cardiac myocytes. Failing hearts show decreased 
catecholamine sensitivity and impaired beta-adrenergic-
receptor density (Hoch and Netz 2005).
Other mechanisms combine to aggravate the deleterious 
consequences of neurohormonal activation, ie:
–  Besides its diuretic effect, aldosterone may enhance inter-
stitial collagen and cause ﬁ  brosis in long-term HF, leading 
to alteration of the diastolic function of the heart.
–  Angiotensin II is thought to induce myocyte apoptose.
–  Abnormal gene expression leads to change in the actin, 
myosin, and collagen isoforms.
–  Lastly, intracellular calcium release may inﬂ  uence sys-
tolic and also diastolic function of the heart.
The combination of the above mechanisms results in 
remodeling of the cardiac structures, through dilation of 
the cavities, hypertrophy, cell death, decrease in capillary 
density, and mitochondrial deﬁ  ciency.
More recent literature provides new insight about the 
mechanisms of HF. In particular, pulmonary and systemic 
congestion seem to be important predictors of both mortality Therapeutics and Clinical Risk Management 2007:3(5) 849
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and morbidity (De Luca et al 2006). Elevated left ventricular 
ﬁ  lling pressures increase pulmonary and right ventricle pres-
sures resulting in pulmonary and systemic congestion. This 
“hemodynamic congestion” may have deleterious effects on 
subendocardial coronary perfusion and drainage from coronary 
veins with subsequent diastolic dysfunction (Georghiade et al 
2006). Pulmonary wedge pressure may be used as a surrogate 
marker of disease progression (Chen and Schrier 2006).
Treatment of HF in children
The rational management of chronic HF in pediatric patients 
requires comprehensive knowledge of the pathophysiological 
mechanisms and must be individualized according to age and 
underlying cardiac disease (Auslander and Artman 2000; 
Clark 2000; Ross 2001).
The beneﬁ  cial effect of diuretics to reduce congestion and 
ﬂ  uid retention is widely accepted. Aldosterone antagonists in 
association with furosemide not only compensate for potas-
sium loss, but also may prevent ﬁ  brosis as a consequence of 
chronic HF and activation of the renin-angiotensin system.
Several trials have demonstrated the signiﬁ  cant beneﬁ  t 
of angiotensin converting enzyme inhibitors on survival 
in adults with chronic HF. These agents can prevent car-
diac remodeling through reduction of angiotensin II and 
aldosterone effects, and decrease myocardial wall stress by 
decreasing cardiac afterload (Stern et al 1990).
Figure 1 The pathophysiological mechanisms of chronic heart failure.
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There is no evidence that digoxin may improve survival 
in patients with chronic HF (Shaddy 2001). Low dose 
to achieve levels ranging from 0.5 to 0.8 ng/mL might, 
however, be beneﬁ  cial (Clark 2000; Hoch and Netz 2005). 
Conversely, the inotropic effect of digoxin is likely to have 
a deleterious effect by increasing myocardial demand (Ross 
2001).
New advances in the treatment of chronic HF in adults 
have highlighted the advantages of beta-blockade strategy to 
improve prognosis (Quaife et al 1997; Lowes et al 1999). It is 
currently accepted that third-generation beta-blocker agents 
like the non-selective carvedilol can affect morbidity and 
mortality in the adult population (Colucci et al 1996; Packer 
et al 1996; Lechat et al 1998). Experience in the pediatric 
population is still limited and drawn from reported research 
on adults. Recent reports have brought divergent insights into 
the beneﬁ  cial effects of beta-blockade strategy in pediatric 
HF patients (Shaddy 2000, 2001).
Beta-blocker agents in chronic 
congestive HF
Mechanisms of action
The mechanisms of action of beta-blockers agents are not yet 
clearly deﬁ  ned and probably impact on the neurohormonal 
component of HF, mainly on the sympathetic activation of 
chronic HF. Through decreasing the sympathetic activation 
of chronic HF, they enable a decrease in heart rate and lower 
myocardial demand.
Studies in adults have demonstrated reversal myocardial 
remodeling (decreased ventricular volumes and spherical 
shape) with concurrent improved ejection fraction and 
shortening fraction (Sackner-Bernstein and Mancini 1995; 
Bristow 1997). Not all the beta-receptor antagonists enable 
reversal of neurohormonal stimulation. The third-generation 
non-selective carvedilol can achieve this. It provides an 
additional α-adrenergic receptor blockade responsible for 
beneficial afterload lowering. From the COMET rand-
omized double-blind trial results, carvedilol had superior 
hemodynamic effects and reduction of all-cause mortality 
compared with metoprolol. These data support the advantage 
of α-adrenergic receptor blockade (Poole-Wilson et al 2003; 
Metra et al 2005) and were conﬁ  rmed by experimental study 
(Nikolaidis et al 2006).
The primary mechanism of these agents is to prevent 
and reverse adrenergically mediated myocardial dysfunc-
tion and remodeling (chamber dilation and assumption of 
a more spherical shape) (Sackner-Bernstein and Mancini 
1995; Bristow 1997; Sabbah 1999). Other mechanisms of 
action have been proposed for the beneﬁ  cial effects of third-
generation beta-blockers in HF, including upregulation of 
beta-receptors, decreased stimulation of other neurohormo-
nal systems, antiarrhythmic effects, coronary vasodilation, 
negative chronotropic effects, antioxidant effects, and 
improved myocardial energetics. In particular, carvedilol 
has an antioxidative effect that may inhibit catecholamine 
ability to generate oxygen free radicals in the myocardium 
(Feuerstein et al 1997; Kaye et al 2001; Nakamura et al 
2002). Both carvedilol and metoprolol have antioxydant 
and antiapoptotic actions, which are likely to be impor-
tant in the treatment of HF (Kawai et al 2004). However, 
carvedilol but not metoprolol was found to inhibit the 
calcium-dependent toxic oxidant species and to increase 
oxygen consumption (Kametani et al 2006). Moreover, 
the chronotopic effect of beta-blockade was shown to be 
one of the major determinants of the restoration of con-
tractile function, as demonstrated in an experimental study 
(Nagatsu et al 2000). The impact of beta-blockers on 
calcium release channel function may also play a signiﬁ  cant 
role in improving myocardial performance (Reiken et al 
2003). Lastly, carvedilol may inhibit endothelin-1 synthesis 
in vitro and prevent vascular smooth muscle cell prolifera-
tion and intimal migration after vascular injury.
Experience in adults 
Most knowledge about beta-blockers efﬁ  cacy in chronic HF 
is drawn from randomized trials performed in adults.
The Metoprolol in Dilated Cardiomyopathy (MDC) trial 
was the ﬁ  rst major multicenter, randomized trial of beta-
blockers in patients with HF (Waagstein et al 1993). In this 
study, 383 patients with idiopathic dilated cardiomyopathy 
were randomized to receive either metoprolol or a placebo. 
Patients who received metoprolol had increased ejection 
fractions and exercise times compared with placebo. The 
Cardiac Insufﬁ  ciency Bisoprolol Study (CIBIS) compared 
the effects of bisoprolol with placebo in 641 adults with 
ischemic and non-ischemic left ventricular dysfunction 
(CIBIS Investigators and Committees 1994), and showed a 
20% reduction in mortality in the bisoprolol group. In 1996, 
one study demonstrated a 65% reduction in mortality in the 
carvedilol group compared with placebo (Packer et al 1996). 
The Multicenter Oral Carvedilol Heart Failure Assessment 
(MOCHA) randomized patients with HF to receive placebo 
or carvedilol (Bristow et al 1996). In this study, carvedilol 
was associated with dose-related improvements in left ven-
tricular function and survival.Therapeutics and Clinical Risk Management 2007:3(5) 851
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Subsequent trials with metoprolol (Merit-HF 1999; Hjal-
marsen et al 2000) and bisoprolol (CIBIS-II 1999) showed 
similar survival beneﬁ  ts in adults with HF. CIBIS-II included 
2647 patients in NYHA class II or IV with left ventricular 
fraction of 35% or less receiving diuretics with inhibitors 
of angiotensin-converting enzyme, who were randomly 
assigned to receive placebo or bisoprolol: all-cause mortality 
was signiﬁ  cantly lower in the treated group (11.8%) com-
pared with placebo (17.3%). Similarly Merit-HF enrolled 
3991 patients in NYHA class II to IV, with ejection fraction 
of 40% or less, to receive either metoprolol or placebo, in 
addition to standard therapy: results also showed a signiﬁ  cant 
reduction of all-cause mortality (7.2% vs 11%).
From these large-scale randomized double-blind 
trials, beta-blockers agents were recommended for the 
treatment of mild to moderate HF, excluding NYHA 
class IV cases. The COPERNICUS trial (Packer et al 
2002) further entered patients with more severe HF: 
2289 patients in NYHA class IV, with ejection fraction 
less than 25%, were randomized to receive either placebo 
or carvedilol for an average of 10.4 months. The results 
showed a significant reduction in the number and dura-
tion of hospitalizations, and in the occurrence of serious 
adverse events (including clinical deterioration, sudden 
death, arrhythmias, and cardiogenic shock).
Experience in children
Table 1 summarizes the current literature about the use of 
beta-blockers in the pediatric HF population.
First experience with beta-receptor antagonist agents 
was reported by Shaddy et al (1999) with the use of meto-
prolol in patients with dilated cardiomyopathy. The authors 
reviewed data from 3 centers. Fifteen patients aged 8.6 ± 
1.3 years and treated over the 1986 to 1997 period were 
included in this study. They received conventional therapy 
for 22.5 ± 9 months, and subsequently a mean dose of 1.1 ± 
0.1 mg/kg/day metoprolol. Eleven patients were responders 
and 4 non-responders; mean follow-up was 23.2 ± 7 months. 
Responders showed a signiﬁ  cant improvement in ejection 
fraction and shortening fraction, while there was no change 
under conventional therapy (before initiation of beta-block-
ers). Eight of 11 responders also improved their NYHA class. 
Since the pre-beta-blocker period was prolonged enough, 
the authors concluded that improvement was more likely 
related to the beneﬁ  cial effect of beta-blockers, rather than 
to spontaneous recovery of left ventricular function.
Table 1 Reported studies about beta-receptor antagonists in pediatric heart failure patients
Ref  N  Design  Cardiac  Beta-  FU Pre  FU Post  Results  Side effects  Outcome
    disease  blocker 
Shaddy  15  Retro  CMD 14  metoprolol  22.5 ± 9   23.2 ± 7   Improved EF, SF, NYHA  Bradycardia  3 dead
1999    Multic  CHD 1    mos  mos  (11 responders)  (1 case)  1 transplant
                1  bradycardia
Bruns  46  Retro  CMD 37  carvedilol    3 mos  Improved SF, NYHA  25 cases (54%)  1 dead
2001   Multic  CHD  9            12  transplant
                1  VAD
Williams  12  Retro   CMD 10  metoprolol  8.5 ± 21  6 mos  Improved EF, SF    5 dead or transplant
2002      CHD 2  and carvedilol  mos       
Rusconi  24  Retro  CMD  carvedilol  14 ± 23  9 mos  Improved EF, NYHA  5 cases  1 death
2004         mos     (21%) 3  heart  transplant
Azeka  22  Prosp  CMD  carvedilol    6 mos  Improved EF, SF, NYHA    6 dead(4 carvedilol,
2002       14         2  placebo)
       Placebo  8         3  transplant
                  (1 carvedilol, 2 placebo)
Shaddy  161  Prosp  CMD  carvedilol  1 mos  6 mos  No signiﬁ  cant change   -  -
2002    Multic  CHD  106      (composite measure of
Cleland    Rando   Placebo     clinical  outcome)
2006       55
Blume  20  Pro  CMD 12  carvedilol  3 mos  6 mos  Improved EF, improved   12 in 6 patients  No difference
2006    Multic  CHD 8  20      composite clinical outcome
      controls
      24
Abbreviations: CMD, cardiomyopathy; CHD, congenital heart disease; EF, ejection fraction; FU, follow-up; mos, months; Multic, multicenter; NYHA, New York Heart As-
sociation; Nb, number of patients; Pre, before onset of beta-blockers; Post, after onset of beta-blockers; Prosp, prospective; Rando, randomized; Ref, reference; SF, shortening
fraction; VAD, ventricular assistance device.Therapeutics and Clinical Risk Management 2007:3(5) 852
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With reference to adult trials (Lechat et al 1998), 
carvedilol was highlighted as the beta-blocker of choice 
to treat chronic HF (Spicer 2001). Bruns et al (2001) ﬁ  rst 
reported multicenter (6 centers) retrospective experience 
with the use of carvedilol in pediatric HF patients, to assess 
efﬁ  cacy, safety, and tolerability. The data from 46 patients 
(aged 3 months to 19 years) with congestive HF due to 
dilated cardiomyopathy (80%) or chronic heart disease 
(20%) were collected and analyzed. Third-month evalua-
tion showed improvement in both clinical NYHA class and 
shortening fraction. Severe adverse outcomes occurred in 
30% (death, transplantation, mechanical ventricular sup-
port). This study, although limited by retrospective analysis, 
was the ﬁ  rst report of consistent data about carvedilol use in 
pediatric patients with chronic HF. Since heart transplanta-
tion is the only ﬁ  nal option in cases with uncontrolled HF, 
and facing the shortage of donors and serious post-transplant 
difﬁ  culties, one major advantage of beta-blockers is that they 
enable heart transplant to be delayed. Azeka et al (2002) 
showed that carvedilol may even allow delisting patients 
from the waiting list.
Two further retrospective studies also conﬁ  rmed the 
beneﬁ  cial effect of beta-blockers on functional outcomes 
and echo Doppler left ventricle function (Williams et al 
2002; Rusconi et al 2004). One main issue is the difﬁ  culty 
of differentiating beta-blocker effect from the natural fa-
vorable evolution of the disease. Left ventricle has been 
shown to spontaneously recover in dilated cardiomyopathy 
or myocarditis or after surgery of abnormal origin of the left 
main coronary artery from the pulmonary artery. Irrevers-
ible systemic ventricle dysfunction should not be assumed 
too soon. Two years is probably the optimal threshold for 
myocardial function to recover; however, follow-up does 
not exceed 6 months in most of the available published 
studies.
Data from prospective studies about carvedilol in children 
with ventricular dysfunction are very limited. One large 
multicenter, prospective, double-blind, placebo-controlled 
study was conducted by Shaddy et al (2002). Patients aged 
0–17 years were included, diagnosed with ejection fraction 
less than 40% at least 4 weeks prior to inclusion, and treated 
with conventional therapy (angiotensin converting enzyme 
inhibitors with one or more other medications). Patients were 
designed to receive either placebo or carvedilol, and were 
followed-up over an 8-month period. Primary end-point was 
a composite of clinical outcomes, determined as worsened, 
improved, or unchanged status (Shaddy et al 2002). Fifty-ﬁ  ve 
patients were included in the placebo group and 106 in the 
carvedilol group, recruited from 20 centers. Results showed 
no difference at 8 months between placebo and treated groups 
for the primary end-point. This study highlighted a higher-
than-expected placebo response rate (Cleland et al 2006). 
Several conclusions can be drawn from these results: 1) the 
heterogeneicity of the population regarding cardiac disease 
and age of the patients may have led to excessive dispari-
ties; 2) we hypothesize that systemic right or single ventricle 
may not act like left ventricle in response to beta-blockers; 
3) neonates have different cardiac physiology, in particular 
lower myocardial compliance, that may have inﬂ  uenced the 
results; 4) cases may have been included that would have 
recovered spontaneously (myocarditis, ischemic injury in 
coronary artery disease); and 5) the length of follow-up 
between diagnosis and onset of beta-blockers may have 
been too short. Conversely, length of follow-up after onset 
of beta-blockers may also be too short to draw conclusions 
on the effectiveness of these agents compared with conven-
tional therapy.
Most recently, Blume et al (2006) reported their results 
of a single-arm protocol of carvedilol in children with ven-
tricular dysfunction lasting for at least 3 months on maximal 
medical treatment including angiotensin converting enzyme 
inhibitors. Twenty carvedilol-treated patients were recruited 
according to clinical and echocardiographic criteria, and 
were compared with historical matched controls. Primary 
end-point was echocardiographic parameters of function 
measured at the sixth month. This study showed a signiﬁ  cant 
increase in ejection fraction in the treated group with dilated 
cardiomyopathy. No conclusion could be drawn in the group 
with congenital heart disease, although some cases experi-
enced echocardiographic improvement similar to patients 
with dilated cardiomyopathy.
In summary, though beta-blockers have been proven 
to affect survival in adults, such an evidence is not yet 
available in the pediatric population. Current practice 
has nevertheless increasingly added beta-blockers to the 
armamentarium, in an attempt to optimize therapy for HF 
in children.
Only limited experience has been reported, mostly from 
retrospective analysis of heterogeneous data. Prospective 
studies are very scarce and results are still a matter of dis-
cussion. The only large-scale, prospective, double-blind and 
placebo-controlled study failed to demonstrate the efﬁ  cacy 
of carvedilol on a composite end-point of clinical outcomes.
However, one may intuitively predict some beneﬁ  cial impact 
of these agents in pediatric HF patients. Further progress will 
be needed to assess this issue.Therapeutics and Clinical Risk Management 2007:3(5) 853
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Current published experience highlights several impor-
tant points:
–  The heterogeneicity of anatomical and pathophysi-
ological factors involved in the development of HF in 
children. A unique feature of pediatrics is the group 
of children with congenital heart disease resulting in 
ventricular dysfunction of a systemic right or single 
ventricle. Many factors play a role to maintain cardiac 
output in chronic heart disease with systemic ventricle 
dysfunction, in particular sinus node (Bullinga et al 
2005). Moreover chronic hypoxemia and ischemia (as 
in adults) probably have different pathophysiological 
effects on myocardial function (Buchhorn et al 2003; 
Giardini et al 2003).
–  The age of the patients that may inﬂ  uence myocardial 
compliance, or even pharmacokinetics (Läer et al 2002) 
and drug interference (Ratnapalan et al 2003).
–  The timing of treatment initiation with beta-block-
ers. Early onset might prevent ventricular remodeling, 
whereas late a onset strategy might help to assess potential 
spontaneous recovery of cardiac function (in the context 
of postoperative injury or myocarditis, or coronary artery 
anomaly).
–  The length of follow-up after onset of beta-blocker treat-
ment should be long enough to better assess efﬁ  cacy.
–  The difference in HF symptoms between children and 
adults. Pediatric patients usually do not present with 
classic symptoms of HF; therefore, relying on clinical 
symptoms may be not sensitive enough to assess.
Tolerability
Beta-blocker agents have been widely and safely used in 
children to prevent acute hypoxemia or supraventricular 
tachycardia, or to treat systemic hypertension. Carvedilol is 
the gold standard for treatment of HF. It is a non-selective 
beta-blocker agent with α-adrenergic effect. Despite its 
impact on systemic resistance, it is usually well tolerated 
when administred through upgrading doses (Krum et al 
2000). Discontinuation of angiotensin converting enzyme 
inhibitors or of beta-blockers because of low blood pressure 
is rarely required.
Conclusion
Although no evidence can be drawn from the literature, it 
is logical to conclude that beta-receptor antagonists may 
provide consistent improvement in myocardial function, 
clinical outcomes, and survival in the pediatric HF popula-
tion. We suggest that further studies are needed to prove 
carvedilol efﬁ  cacy in children and select patients who would 
better beneﬁ  t from it. Selection of an homogeneous group 
and longer follow-up would probably help to enhance the 
power of such studies.
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